In Warm Springs, Oregon, the love of basketball is uniting a community against #PancreaticCancer. This aggressive disease disproportionately affects Native American communities, with a grim survival rate. But a new partnership at OHSU is aiming to change that narrative ⤵️

Join us for this year’s Early Detection of Cancer conference! 🗓️ Oct. 21-23 📍Portland, OR 🤝 @cancerresearchuk.org, Canary Center at Stanford The conference will be packed with discussions, lightning talks from submitted abstracts, and networking opportunities. Register ⤵️

September is Prostate Cancer Awareness Month 🩵 Here are 4️⃣ facts to know about #ProstateCancer. Share these with a friend, a family member, or a loved one.

VC firm Next Ventures has partnered with @ohsunews.bsky.social to support the expansion of its cancer institute @ohsuknight.bsky.social thenextleap.is/news/next-ve...

Dr. Alexandra Sokolova discusses the TRIPLE-SWITCH trial, a study that addresses treatment intensification in metastatic hormone-sensitive #ProstateCancer. Watch (via Urology Today): https://bit.ly/41Cekoc

Dr. Alexandra Sokolova discusses the TRIPLE-SWITCH trial, a study that addresses treatment intensification in metastatic hormone-sensitive #ProstateCancer. Watch (via Urology Today): https://bit.ly/41Cekoc

Dr. Alexandra Sokolova discusses the TRIPLE-SWITCH trial, a study that addresses treatment intensification in metastatic hormone-sensitive #ProstateCancer. Watch (via Urology Today): https://bit.ly/41Cekoc

Collaborations are key in our battle against cancer. On Thursday, we had the privilege of hosting Lance Armstrong and Next Ventures at @ohsuknight.bsky.social. Discussions centered on whole person health solutions and partnering to #GiveCancerHell. 📸 Liz Kreutz

Calling all cancer researchers! Join us, @ohsuknight.bsky.social and @stanford.edu at this year's Early Detection of Cancer Conference for the cutting-edge, cross-disciplinary science that is shaping the future of cancer early detection. Check out the agenda and register: cruk.ink/3UR67Zu

September is Prostate Cancer Awareness Month 🩵 Here are 4️⃣ facts to know about prostate cancer. Share these with a friend, a family member, or a loved one.

“The most modifiable factor for getting skin cancer is exposure to UV radiation. Being at altitude, you’re closer to the sun, so just by being outside in the sun you get exposed to more UV radiation.” - Dr. Elizabeth Berry on the risk of #Melanoma in mountain communities (Idaho Mountain Express):

“To move from this study to an AI tool that recognizes vocal fold lesions, we would train models using an even larger dataset of voice recordings, labeled by professionals.” - Dr. Phillip Jenkins on using AI to help detect #LaryngealCancer #OHSUResearch: https://bit.ly/4fH4NBP

“We shouldn’t be afraid of being outrageously ambitious and doing something great in Oregon.” Dr. Brian Druker joined OPB's "Think Out Loud" to discuss what Phil and Penny Knight's $2 billion donation will mean for cancer care in Oregon. #GiveCancerHell

A study led by OHSU and Portland State University finds cancerous vocal fold lesions could exert a subtle influence over the sound of a person's voice, which could help catch #LaryngealCancer earlier than current methods. #OHSUResearch: https://bit.ly/4fH4NBP

“It tells us there’s a signal here. We wouldn’t have expected these rates of high-risk adenomas, which are cancer precursor lesions, in an age group like this.” - Dr. David Lieberman on the possibility of extreme exercise being linked to #ColonCancer:

Dr. Elizabeth Berry weighs in on the risk of #Melanoma in mountain communities (via The Idaho Mountain Express):

What will Phil and Penny Knight's $2 billion donation mean for cancer care in Oregon? Dr. Brian Druker joined @opb.org's "Think Out Loud" to discuss. #GiveCancerHell

"I would run through a brick wall for you!" Dan Lanning's voiceover in the #GiveCancerHell video inspired Dr. Brian Druker to call the Oregon Football Head Coach 🤝

Employees gathered on the Mackenzie Hall lawn to recognize their incredible work and to toast to the Knight's historic gift. It was a time for fellowship, reflection on what had been accomplished, and the opportunities that lay ahead. Together, we will #GiveCancerHell.

"We couldn’t be more excited about the transformational potential of this work for humanity." - Phil and Penny Knight on their historic $2 billion gift to @ohsuknight.bsky.social to transform the future of cancer care and set a new standard globally. #GiveCancerHell

Phil and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s Knight Cancer Institute to transform the future of cancer care and set a new standard globally. Thank you to Phil and Penny Knight for their incredible generosity. #GiveCancerHell

This fight is and always will be personal. Together let's #GiveCancerHell

In Warm Springs, Oregon the love of basketball is uniting a community against #PancreaticCancer. This aggressive disease disproportionately affects Native American communities, with a grim survival rate. But a new partnership at OHSU is aiming to change that narrative ⤵️

🔬 10 years in the making 🔬 A collaboration among OHSU, Indiana University, University of Maryland, and Johns Hopkins produced mathematical models that could begin to unlock how groups of cells will respond to various cancer therapy combinations. #OHSUResearch ⤵️

Congrats to @ohsuknight.bsky.social Bertassoni Lab on their @nidcr.bsky.social grant! 🎉 The team will develop a “tumor-bone interface on-a-chip” to study how oral cancer spreads & destroys bone, enabling a personalized approach to risk assessments & drug development. 🧪 news.ohsu.edu/2025/07/28/o...

“With this tool, we can estimate the fractions of those populations defined by single-cell data in bulk data from patient groups. It could help us understand which cell populations are changing during disease progression and guide treatment decisions.” - Dr. Zheng Xia on the OmicsTweezer tool ⤵️

"The PAC-MANN assay requires such a minuscule volume of blood." - Dr. Jared Fischer on the new blood test developed at OHSU used to help identify #PancreaticCancer #OHSUResearch ⤵️

"We can develop new therapies and test cells from individual patients to check which ones are more likely to spread. This is a powerful way of determining risk of more serious disease before tumors begin to spread and grow.” - Dr. Luiz Bertassoni on a new organ-on-a-chip model: bit.ly/4me4ksO

What's next after researching alpha-synuclein's role in targeting #Melanoma? Dr. Vivek Unni and team hope to explore the role of gamma-synuclein, which is known to be raised in breast and lung cancer cells. #OHSUResearch ➡️ bit.ly/3Ur9VQO

ICYMI: A nationwide research collaboration between 5 labs has resulted in digital models that could begin to unlock how groups of cells will respond to cancer treatment combinations. #OHSUResearch ➡️ bit.ly/4lJS3fX

Using robotics to treat #ProstateCancer 🩵🦾 Dr. Sudhir Isharwal uses a non-invasive robotic device that utilizes high frequency, focused ultrasound waves to treat the cancer. OHSU was the first hospital in Oregon to offer the treatment:

Researchers at OHSU have been awarded $3.5 million in federal funding to study the interactions of oral cancer with bone using advanced organ-on-a-chip models. The chip-based system mimics key components of the bone environment, including mineral matrix, osteoblasts, osteoclasts and blood vessels.

New #OHSUResearch shows a link between #Parkinsons disease and #Melanoma. 🔬 A new study led by Dr. Vivek Unni suggests that a protein (alpha-synuclein) involved in Parkinson’s disease accumulates in the nucleus of cells in the skin and plays a role in the formation of the skin cancer melanoma.

5 labs, 2 years, 1 goal: Solving the equations of cancer cell behavior 🔬 A nationwide research collaboration between 5 labs has resulted in digital models that could begin to unlock how groups of cells will respond to cancer treatment combinations.

Congratulations to Dr. Shivaani Kummar on being honored with the prestigious 2024 National Cancer Institute Director’s Award! The award is one of the NCI’s highest accolades and is bestowed upon those who demonstrate excellence, innovation, and commitment throughout their organization.

“This study provides a framework for understanding the link between Parkinson’s disease and melanoma and offers potential therapeutic targets in melanoma that are focused on reducing aSyn-mediated nucleolar double-strand break repair." - Dr. Vivek Unni on #OHSUResearch surrounding alpha-synuclein ⤵️

Congratulations to Dr. Tanaya Shree on receiving the 2025 @damonrunyon.org Clinical Investigator Award! The recipients of this award are outstanding, early-career physician-scientists conducting patient-oriented cancer research under the mentorship of the nation's leading scientists and clinicians.

“The tumor microenvironment, made up of diverse cell types that shape tumor development and patient outcomes, has been a longstanding research priority at @ohsuknight.bsky.social.” - Dr. Zheng Xia on new #OHSUResearch aiming to improve tissue cancer analysis

Will liquid biopsies transform cancer care? Scientists Jared Fischer and Luis Montoya Mira participated in an @healthjournalism.org panel to discuss the topic at hand, including their accuracy, need for follow-up tests, and more ⤵️

Honored to be selected as a Damon Runyon Clinical Investigator among this group of incredible scientists and appreciative of the support to conduct patient-centered mechanistic research. @ohsunews.bsky.social @ohsuknight.bsky.social #CancerImmunotherapy #LymphomaResearch

🔬New #OHSUResearch🔬 Researchers have developed a powerful new tool, called OmicsTweezer, that makes it easier to study the mix of cell types in human tissue, which is crucial for understanding diseases such as #Cancer.

New #OHSUResearch provides a new understanding of the αSyn protein’s dual role and context to long-standing observations that people with #ParkinsonsDisease are significantly more likely to develop #melanoma, and vice versa. insideprecisionmedicine.com/topics/preci... cc: @ohsuknight.bsky.social

Research from Dr. Curtis Lachowiez evaluated thresholds for clinical and molecular parameters which refine disease classification across myeloid malignancies. The findings will inform the future @who.int 6th edition classification system for myeloid neoplasms (@theaacr.bsky.social): bit.ly/44vcFRL

A study led by Dr. Curtis Lachowiez evaluated thresholds for clinical and molecular parameters which refine disease classification across myeloid malignancies. The research unifies @who.int and Intl. Consensus Classification Guidelines for myeloid neoplasms (@theaacr.bsky.social): bit.ly/44vcFRL

ICYMI: Our Community Partnership Program has invested more than $6.4 million in 238 projects around Oregon since 2014! Learn more about our latest funding round set to empower 12 new projects that will address cancer-related needs across the state: bit.ly/4kmvIDD

Researchers at OHSU collaborated with @oregonstate.edu on a new way to treat respiratory diseases by developing a new drug delivery system that transports genetic therapies directly to the lungs. The breakthrough open promising possibilities for patients with conditions like #LungCancer ⤵️

Congratulations to the Youth HPV Champions on receiving the prestigious “Change Maker Award” at the annual B.I.L.L.I.E.S. Youth Summit and Award Show! The Youth HPV Champions are dedicated to promoting HPV prevention among peers and this honor is a testament to their work within the community. 👏

From education to prevention and survivorship, the Community Partnership Program funds diverse community-generated ideas to address the burden of cancer. Since it began in 2014, the Community Partnership Program has invested more than $6.4 million in 238 projects around Oregon!

Researchers at OHSU collaborated with @oregonstate.edu on a new way to treat respiratory diseases by developing a new drug delivery system that transports genetic therapies directly to the lungs. The breakthrough open promising possibilities for patients with conditions like #LungCancer ⤵️

Two recipients with @ohsuknight.bsky.social ties🔬 • Dr. Jeff Tyner's research focuses on identifying cancer-causing genes and creating patient-tailored therapies. • Dr. Shelly Tworoger is improving prevention recommendations and identifying women at high risk of breast/ovarian cancers. More ⤵️